anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to medicine, namely to devices for treatment of bacterial and viral vaginoses, inflammatory diseases of lower segements of genitals. A device for vaginal introduction of medications contains a tip, made with an axial through channel. The end of entered tip is spherical, and opposite end is provided with a cylinder with a flange and two branch pipes, inlet and outlet ones. The axial through channel of tip is connected with the inlet branch pipe. An additional through channel is made in the cylinder, which is conncted with the outlet branch pipe and locted in parallel to the axial through channel. And external surface of the tip, located between spherical end and cylinder, is mase as screw one. The device for vaginal introduction of drugs, including ozone-oxygen mixtures or ozonated liquids, allow to conduct treatment significantly exceeding conventional one both in efficiency od antimicrobial action and in amount of obtained positive results.
Anesthesia staff will suction secretions intermittently using an intermittent suction regulator. The regulator will be set to suction at 100-150 mmHg. The regulator has a preset cycle of intermittent suctioning for 15 seconds with an 8 second pause.
1,253,500. Contraceptive method. SCHERING A.G. 19 April, 1968 [19 April, 1967], No. 1714/71. Divided out of 1,231,412. Heading A5B. A method of contraception comprises the administration to a human female, parenterally or by implantation, of a gestagen free from oestrogens in a dose as hereinafter defined in any single menstrual cycle. The gestagen dosage is defined as that having an effect on the cervical mucus which corresponds to that produced by 1 to 20 mg. of 19-nor-17α-hydroxy progesterone caproate when administered in the same way. The term "gestagen" refers to progestational hormones (progestogens or progestins) having a pituitary hypothalamic inhibiting action or which have such action only at a dose above the minimum dose which produces gestagenic action. Typical compounds are: progesterone; its 3-enol esters and 17α-hydroxy-deviations, the 17-esters of 6α- methyl-17α-hydroxy progesterone and 17α- ethynyl-18-homo-19-nor-testosterone and its esters.
Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (\<) 20 x10\^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
The present invention pertains to a process for the high-efficiency hydration of gut flora in the colon (large intestine). In the course of the process, an arbitrary mass of homogenous, compact, rubbery prepared kombucha fungal culture is cleaned, then placed in a blending device with a blade suited to mincing the culture into smaller pieces, into which a quantity of water equal to the mass of the original kombucha culture is also poured. The process is characterised in that, depending on the water content required, the kombucha fungal culture is ground or minced into pieces on the order of a millimetre in size using a high-speed blending device, then pulped until a gel of a maximum water content of 95% (g/lOOg) is obtained, which gel, when passed into the colon, is used to cleanse the intestinal tract and promote absorption. After this, a quantity of water equal to the mass of the initial kombucha culture is added to the gel produced as above and the mixture pulped using a blending device for at least a half an hour until the aqueous phase disappears. At this point, using the sharp blades of the blending device rotating at a speed of at least 2000 rotations per minute, gaps on the order of tenths or hundredths of a millimetre in size are created in the fibrous structure of the kombucha culture into which water is absorbed on the basis of the principle of capillary action. Thus, a fine, pulpy gel having a water content of more than 95% and no separate aqueous phase or remaining substance to be gelatinated or pulped is obtained, which gel is used to hydrate existing gut flora or, in the event of a probiotic therapy, when passed into the colon, to supply water to the microbes taken with the probiotics.
Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
Participants with melanoma brain metastases undergo STAR DCE-MRI at baseline and 4-6 weeks after therapy. Participants may undergo more frequent MRI if there is concern for tumor progression.
Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.
Metastasis is the major cause of treatment failure in patients with prostate adenocarcinoma (PRAD). Diverse programmed cell death (PCD) patterns play an important role in tumor metastasis and hold promise as predictive indicators for PRAD metastasis. Using the LASSO Cox regression method, we developed PCD score (PCDS) based on differentially expressed genes (DEGs) associated with PCD. Clinical correlation, external validation, functional enrichment analysis, mutation landscape analysis, tumor immune environment analysis, and immunotherapy analysis were conducted. The role of Prostaglandin D2 Synthase (PTGDS) in PRAD was examined through in vitro experiments, single-cell, and Mendelian randomization (MR) analysis. PCDS is elevated in patients with higher Gleason scores, higher T stage, biochemical recurrence (BCR), and higher prostate-specific antigen (PSA) levels. Individuals with higher PCDS are prone to metastasis, metastasis after BCR, BCR, and castration resistance. Moreover, PRAD patients with low PCDS responded positively to immunotherapy. Random forest analysis and Mendelian randomization analysis identified PTGDS as the top gene associated with PRAD metastasis and in vitro experiments revealed that PTGDS was considerably downregulated in PRAD cells against normal prostate cells. Furthermore, the overexpression of PTGDS was found to suppress the migration, invasion, proliferationof DU145 and LNCaP cells. To sum up, PCDS may be a useful biomarker for forecasting the possibility of metastasis, recurrence, castration resistance, and the efficacy of immunotherapy in PRAD patients. Additionally, PTGDS was identified as a viable therapeutic target for the management of PRAD.
Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
Monitoring of prevalent airborne diseases such as COVID-19 characteristically involves respiratory assessments. While auscultation is a mainstream method for preliminary screening of disease symptoms, its utility is hampered by the need for dedicated hospital visits. Remote monitoring based on recordings of respiratory sounds on portable devices is a promising alternative, which can assist in early assessment of COVID-19 that primarily affects the lower respiratory tract. In this study, we introduce a novel deep learning approach to distinguish patients with COVID-19 from healthy controls given audio recordings of cough or breathing sounds. The proposed approach leverages a novel hierarchical spectrogram transformer (HST) on spectrogram representations of respiratory sounds. HST embodies self-attention mechanisms over local windows in spectrograms, and window size is progressively grown over model stages to capture local to global context. HST is compared against state-of-the-art conventional and deep-learning baselines. Demonstrations on crowd-sourced multi-national datasets indicate that HST outperforms competing methods, achieving over 90% area under the receiver operating characteristic curve (AUC) in detecting COVID-19 cases.
The invention relates to a preparation method of a medicine for regulating qi and blood and fixing hair and teeth. The medicine is prepared in form of capsules and pills through screening, cleaning, drying, cauterizing, frying, mixing, crushing, mesh screening, mixing and packaging based on rhizoma atractylodis, the root of red-rooted salvia, medlar, Chinese yam, pericarpium zanthoxyli, Poria cocos, liquorice, elecampane, monkshood and fennel as raw materials. The preparation method provided by the invention has the advantages of scientific formula, accurate dosage, low cost, convenient administration, remarkable effect and no side effect. The medicine provided by the invention inherits and carries forward fine tradition of traditional Chinese medicine and is in accordance with green and healthy lifestyle purchased by people at present. Under the premise of latest research, based on folk remedy and sticking to treatment determination based on syndrome differentiation in traditional Chinese medicine, the medicine is formulated to suite the case and is scientific in compatibility, and has the remarkable effects of regulating qi and blood, tonifying viscera, strengthening the body resistance and assisting treatment. Meanwhile, clinical observation for a patient taking the medicine shows that the medicine is especially remarkable to fix hair and teeth, and improving the appearance.
The present invention discloses a quick-acting analgesic and antipruritic tincture. Evodia fruit, frankincense, myrrh, rhizoma corydalis, stemona, long pepper, benzoin, borneol and dried alum are pulverized, are added to ethanol and are immersed at normal temperature; camphora, menthol and styrax oil are added for agitation and filtration, and the obtained filter liquid is the prepared quick-acting analgesic and antipruritic tincture. The present invention has the effects of warming channels, dispelling cold, disinfesting insects, detoxicating, alleviating pain and relieving itching, and can be used for treating traumatic injury, toothache, headaches, trigeminal neuralgia, stomachaches, frostbite, scalds, skin titillation, mosquito bite, pubic louse trichomonas vaginitis, hemorrhoid, etc. The quick-acting analgesic and antipruritic tincture can be used as a spraying agent, and can be also used as liniment. The present invention has the obvious characteristics of high speed for alleviating pain, broad application range, no poison, no stimulation, no side effect and convenient use. After the tincture is sprayed or applied for several seconds, pain dies away.
Background and Objectives: Wound healing encompasses a multitude of factors and entails the establishment of interactions among components of the basement membrane. The quantification of particle concentrations can serve as valuable biomarkers for assessing biomechanical muscle properties. The objective of this study was to examine the immunoexpression and immunoconcentration of myometrial collagen type VI, elastin, alpha-smooth muscle actin, and smooth muscle myosin heavy chain, as well as the expression of platelets and clusters of differentiation 31 in the uterine scar following a cesarean section (CS). Materials and Methods: A total of 177 biopsies were procured from a cohort of pregnant women who were healthy, specifically during the surgical procedure of CS. The participants were categorized into seven distinct groups. Group 1 consisted of primiparas, with a total of 52 individuals. The subsequent groups were organized based on the duration of time that had elapsed since their previous CS. The analysis focused on the immunoexpression and immunoconcentration of the particles listed. Results: No significant variations were observed in the myometrial immunoconcentration of collagen type VI, elastin, smooth muscle myosin, and endothelial cell cluster of differentiation 31 among the analyzed groups. The concentration of alpha-smooth muscle actin in the myometrium was found to be significantly higher in patients who underwent CS within a period of less than 2 years since their previous CS, compared to those with a longer interval between procedures. Conclusions: Our findings indicate that the immunoconcentration of uterine myometrial scar collagen type VI, elastin, smooth muscle myosin heavy chain, alpha-smooth muscle actin, and endothelial cell marker cluster of differentiation 31 remains consistent regardless of the duration elapsed since the previous CS. The findings indicate that there are no significant alterations in the biomechanical properties of the uterine muscle beyond a period of 13 months following a CS.
Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
In a method for treating lung diseases, a drug formulation is prepared by combining micronized crystalline beclomethasone dipropionate and lactose. The drug formulation is placed into a dry powder inhaler which provides inhalable drug particles having a mass median diameter of about 0.5-5.8 microns. The inhaler is preferably largely flow rate independent. Drug and lactose particles are separated in the inhaler during inhalation, most desirably via a spinning element. Due to deep deposition, the drug particles persist in the lungs for a surprisingly long duration, increasing the therapeutic effect of each dose. The patient inhales the drug particles with an inspiratory flow rate of about 10-60 liters/minute, to produce a deep lung deposition of inhaled particles.
The present invention relates to a mask pack sheet and, more particularly, to a mask pack sheet made of a non-woven fiber aggregate comprising lyocell fiber. The mask pack sheet is made of a non-woven fiber aggregate comprising lyocell fiber, and is characterized in that the fineness of the lyocell fiber is 1.0 to 1.4 denier. The mask pack sheet according to the present invention is made of a non-woven fiber aggregate comprising lyocell fiber and thus has improved flexibility. Accordingly, the mask pack sheet does not detach from the skin even after a long period of wearing, and has improved attachment to skin. The degree of absorption of essence or moisture and the transparency after essence or moisture treatment can be improved. In addition, the mask pack sheet can be used as a mask pack supporter sheet, thereby improving the attachment to skin and the feeling of wearing, and the excellent absorption enables effective supply of nutrients to the skin. Furthermore, the wet transparency is improved such that, when the mask pack sheet is tightly attached to the user's face, the color of the mask pack sheet appears transparent rather than white when the user's face is seen from the outside. Accordingly, the color of the mask pack sheet looks close to the color of the user's face such that less difference in appearance is noticeable, thereby providing an aesthetic appearance after wearing the mask pack.
The aim of the study is to assess the suitability of the herbal formulation for topical application as a skin burn dressing on the in vivo wound-closure of third-degree wound injuries. Rat wound models were used to prove the in vivo skin burn-healing process. Body weight gain, food and water intake, and behavior were investigated daily during treatment period. Cutaneous biopsies of the burned wound surfaces were monitored at days 4, 13, and 28. Formulation markedly (P < .05) increased wound repair rate and collagen production compared to untreated burnt skin. Macroscopic and histological analysis of the wound of formula (F)-treated group showed significant skin contraction rate and rapid wound healing without scar through regeneration of epidermis that were approved in formula mixed with honey (F-hY)- and Drs-treated wound compared with thymol, and the untreated wound tissues that were not covered by denuded epithelial. Furthermore, the wound healing efficacy of F-hY, F, and Drs cream was proved by decreased the amount of malondialdehyde compared to untreated rats. In conclusion, F and F-hY was found to promote cutaneous wound repair. In all case, the formula alone or mixed with honeybees was even better than thymol in the repair of cutaneous wound.
The safety and efficacy of EPIVIR-HBV were evaluated in a double-blind clinical trial in 286 subjects aged from 2 to 17 years, who were randomized (2:1) to receive 52 weeks of EPIVIR-HBV (3 mg per kg once daily to a maximum of 100 mg once daily) or placebo. All subjects had compensated chronic hepatitis B accompanied by evidence of hepatitis B virus replication (positive serum HBeAg and positive for serum HBV DNA by a research branched-chain DNA assay) and persistently elevated serum ALT levels. The combination of loss of HBeAg and reduction of HBV DNA to below the assay limit of the research assay, evaluated at Week 52, was observed in 23% of subjects treated with EPIVIR-HBV and 13% of placebo-treated subjects. Normalization of serum ALT was achieved and maintained to Week 52 more frequently in subjects treated with EPIVIR-HBV compared with placebo (55% versus 13%). As in the adult controlled trials, most subjects treated with EPIVIR-HBV had decreases in HBV DNA below the assay limit early in treatment, but about one third of subjects with this initial response had reappearance of assay-detectable HBV DNA during treatment. Adolescents (aged 13 to 17 years) showed less evidence of treatment effect than younger pediatric subjects.
Facial paralysis is the inability to move facial muscles thereby impairing the ability to blink and make facial expressions. Depending on the localization of the nerve malfunction it is subcategorised into central or peripheral and is usually unilateral. This leads to health deficits stemming from corneal dryness and social ostracization.Objective: Electrical stimulation shows promise as a method through which to restore the blink function and as a result improve eye health. However, it is unknown whether a real-time, myoelectrically controlled, neurostimulating device can be used as assistance to this pathological condition.Approach: We developed NEURO-BLINK, a wearable robotic system, that can detect the volitional healthy contralateral blink through electromyography and electrically stimulate the impaired subcutaneous facial nerve and orbicularis oculi muscle to compensate for lost blink function. Alongside the system, we developed a method to evaluate optimal electrode placement through the relationship between blink amplitude and injected charge.Main results: Ten patients with unilateral facial palsy were enrolled in the NEURO-BLINK study, with eight completing testing under two conditions. (1) where the stimulation was cued with an auditory signal (i.e. paced controlled) and (2) synchronized with the natural blink (i.e. myoelectrically controlled). In both scenarios, overall eye closure (distance between eyelids) and cornea coverage measured with high FPS video were found to significantly improve when measured in real-time, while no significant clinical changes were found immediately after use.Significance: This work takes steps towards the development of a portable medical device for blink restoration and facial stimulation which has the potential to improve long-term ocular health.
An apparatus, method and computer program for generating and delivering a multimodal digital therapy signal is disclosed. The apparatus comprises an interface configured to receive at least one biometric signal, a multimodal digital therapy generator comprising an analyser configured to analyse the biometric signal and to generate a multimodal digital therapy based upon it and a desired outcome. An output mechanism is configured to provide the generated multimodal digital therapy. The analyser is configured to monitor changes in the biometric signal in response to the multimodal digital therapy and to determine whether the changes indicate an approach towards the desired outcome, and to modify the multimodal digital therapy in response to changes indicating a movement away from the desired outcome. The interface may be configured to receive signals from the user indicative of mood. The digital therapy may comprise cues for inhaling and exhaling and the changes may include an estimated reduction in stress.
OBJECTIVES: I. Compare the progression free survival of chemotherapy naive patients with stage IC-IV ovarian epithelial cancer following initial surgery treated with paclitaxel and carboplatin versus docetaxel and carboplatin. II. Compare the toxic effects of these regimens in these patients. III. Determine the overall survival, overall response rate, and CA125 response in these patients after these regimens. IV. Determine the quality of life of these patients on these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by residual disease (none or microscopic vs macroscopic no greater than 2 cm vs or macroscopic greater than 2 cm), study center, FIGO stage (IC-IV), performance status (0 vs 1 vs 2), tumor grade (well-defined vs moderately defined vs poorly defined/undifferentiated vs unknown), interval debulking intention (yes vs no vs randomized into OV06 trial), elevated CA125 prior to treatment (yes vs no), and primary peritoneal cancer (yes vs no). Patients may undergo interval debulking surgery within 4 weeks of the third course of chemotherapy, or following 6 courses of treatment. Patients undergoing interval debulking after 3 courses should resume chemotherapy within 3 weeks of surgery. Patients are randomized into one of two treatment arms. Arm I: Patients receive paclitaxel IV over 3 hours, immediately followed by carboplatin IV over 1 hour. Arm II: Patients receive docetaxel IV over 1 hour, immediately followed by carboplatin IV over 1 hour. Courses are repeated every 21 days. Treatment continues for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial or complete response may receive 3 additional courses of carboplatin alone thereafter. Quality of life is assessed at baseline, prior to each treatment course, and then every 4 months for 2 years or until disease progression. Patients are followed every 2 months for 2 years, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months thereafter.

PROJECTED ACCRUAL: Approximately 1050 patients will be accrued for this study within 2.25 years.